Wantstats
Company ProfilePremium

Dynavax Technologies

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Dynavax Technologies - Healthcare showcase

Year Founded & Workforce

1996

351 Employees

Industry

Healthcare
D

Dynavax Technologies Employee Contacts

40 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Dynavax Technologies Overview

Company Headquarters: California, US

Founded: 1996

Workforce: ~351

Company Working: Dynavax Technologies is a commercial-stage biopharmaceutical business with extensive experience and skill in vaccine development and commercialization. The company has established several clinical and preclinical collaborations with vaccine developers to evaluate vaccine product candidates against influenza, other infectious diseases, and particularly COVID-19 across a variety of vaccine platforms. It is focused on building an innovative pipeline of investigational vaccine product candidates, leveraging its proven, proprietary vaccine adjuvant technology

Strategy

Establishing collaborative agreements to help fund the development and commercialization of its product candidates and research programs is a significant component of Dynavax Technologies’ business strategy for items in development. The principal goals of the company are to make HEPLISAV-B the standard of treatment in the US for adult hepatitis B immunization and to establish CpG 1018 as a premier vaccine adjuvant

Company Snapshot

351

Employees

1996

Founded

California, US

Headquarters

Key Developments

DateApproachDevelopment
May 2021–Dynavax Technologies announced a commercialization agreement with Bavarian Nordic (Denmark) to market and distribute HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany.
July 2020–Dynavax Technologies and the Icahn School of Medicine at Mount Sinai ("Mount Sinai") have established a collaboration to develop a universal influenza (flu) vaccine. Mount Sinai's current work in this field is supported by a contract award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) as part of the NIAID-established Collaborative Influenza Vaccine Innovation Centers (CIVICs).

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →